A., Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients, Journal of the American Academy of Dermatology 76, no
Nayan Patel, PharmD, founder of Auro Wellness and CEO of Central Drugs Compounding Pharmacy
Retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptors, has shown even more dramatic weight loss in clinical trials, with some participants losing over 25% of their body weight
[35] Orforglipron Orforglipron is an oral non-peptide small-molecule GLP-1 receptor agonist approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, in combination with reduced-calorie diet and increased physical activity
Lets get into the detailsso you can determine if these medications are right for you